Major source of antigenic peptides for the MHC class I pathway is produced during the pioneer round of mRNA translation. - Wikidata - awgldk - TriplyDB

Major source of antigenic peptides for the MHC class I pathway is produced during the pioneer round of mRNA translation.

Major source of antigenic peptides for the MHC class I pathway is produced during the pioneer round of mRNA translation.

http://www.wikidata.org/entity/Q35105327

about

RAN translation and frameshifting as translational challenges at simple repeats of human neurodegenerative disorders DRiPs solidify: progress in understanding endogenous MHC class I antigen processing Mass Spectrometry of Human Leukocyte Antigen Class I Peptidomes Reveals Strong Effects of Protein Abundance and Turnover on Antigen Presentation Pathways of antigen processing.A critical analysis of codon optimization in human therapeutics.The mRNP remodeling mediated by UPF1 promotes rapid degradation of replication-dependent histone mRNA.Nuclear translation visualized by ribosome-bound nascent chain puromycylation.Proteome sampling by the HLA class I antigen processing pathway Translation of pre-spliced RNAs in the nuclear compartment generates peptides for the MHC class I pathway eIF4AIII enhances translation of nuclear cap-binding complex-bound mRNAs by promoting disruption of secondary structures in 5'UTR.Kinetics of antigen expression and epitope presentation during virus infection.Early Kinetics of the HLA Class I-Associated Peptidome of MVA.HIVconsv-Infected Cells.Regulation of cytoplasmic mRNA decay.Using intein catalysis to probe the origin of major histocompatibility complex class I-presented peptides Rapid degradation of replication-dependent histone mRNAs largely occurs on mRNAs bound by nuclear cap-binding proteins 80 and 20 Rescue of nonsense mutations by amlexanox in human cells.Amsterdamming DRiPs.Nuclear translation for immunosurveillance.Design of an Optimized Wilms' Tumor 1 (WT1) mRNA Construct for Enhanced WT1 Expression and Improved Immunogenicity In Vitro and In Vivo Going Pro to enhance T-cell immunogenicity: easy as π?Translating DRiPs: MHC class I immunosurveillance of pathogens and tumors.A yeast-based assay identifies drugs that interfere with immune evasion of the Epstein-Barr virus.Re-examining class-I presentation and the DRiP hypothesis The nature and extent of contributions by defective ribosome products to the HLA peptidome.Post-transcriptional regulatory networks in immunity.The impact of macroautophagy on CD8(+) T-cell-mediated antiviral immunity.Cap-binding complex (CBC).Epstein-Barr virus-encoded EBNA1 and ZEBRA: targets for therapeutic strategies against EBV-carrying cancers.Lymphocyte repertoire selection and intracellular self/non-self-discrimination: historical overview.TAPBPR: a new player in the MHC class I presentation pathway.MHC structure and function - antigen presentation. Part 2 I've got algorithm: predicting tumor and autoimmune peptide targets for CD8+ T cells.Regulation of protein synthesis and autophagy in activated dendritic cells: implications for antigen processing and presentation.Alternative Start Sites Downstream of Non-Sense Mutations Drive Antigen Presentation and Tolerance Induction to C-Terminal Epitopes.Autoimmune T cell recognition of alternative-reading-frame-encoded peptides.Varied Role of Ubiquitylation in Generating MHC Class I Peptide Ligands.Exosome-driven transfer of tumor-associated Pioneer Translation Products (TA-PTPs) for the MHC class I cross-presentation pathway.Global proteogenomic analysis of human MHC class I-associated peptides derived from non-canonical reading frames.Substrate-induced protein stabilization reveals a predominant contribution from mature proteins to peptides presented on MHC class I.Developing a potentially immunologically inert tetracycline-regulatable viral vector for gene therapy in the peripheral nerve.

P2860

Q26823908-06533EBC-84C3-44DB-875D-2764F549D5F5 Q27006750-58275220-6F05-48A6-872C-3D5A57A96E11 Q30002365-97364C47-7B3C-40C0-B69E-54808C878EA5 Q33631854-4BF3901D-4911-49BE-ABA7-2C600328B731 Q34042157-698EBEC8-2447-4372-907B-B36A88ECA9B9 Q34044351-1A05E957-700D-4CFC-BA03-070CEB4949C3 Q34265585-66FF2227-6394-4FB5-8056-AC465B63E406 Q34276972-B06AEAEC-54D6-42F2-B646-590FFDA00EE2 Q34374454-63FBDA0E-F28C-45BB-929B-627D6B8F613E Q34442451-19728CFE-D2E3-49DD-81D0-A2F92E384492 Q34574829-6D596F22-03AE-4108-BE03-8F540A8B8BC9 Q35641132-7B2E12F6-5D5E-49DA-8ACA-3BF441DE470F Q35955726-30E6AF6E-8161-4FC4-B14F-7A5677350431 Q36342549-547B3CA3-E7B9-4DFC-BD1C-AB2C8083FD51 Q36559271-B1D767F1-52D7-4F2F-81F9-3E82BE86A300 Q36581500-4988C9C7-4F99-48C9-A8F7-89B89B6C1294 Q36724559-BC4561F7-D9C0-445A-92AE-C13BD964A873 Q37276555-71C30340-06B4-4DA9-A459-BCE8657E5970 Q37467831-33A9CBCB-09C8-4CE7-ACC3-239742208123 Q37474545-52117FF1-BF2D-48DA-8224-18F4B2D13A94 Q37644973-9D09643B-A34C-45F0-857C-78FA83772C9F Q37682377-31DA5287-FB13-4E35-999F-93341D2379A5 Q37702916-97A39745-25C4-44A2-BA3B-559FB69ACBF0 Q37725183-D0EAD7EA-AE98-415A-82FF-97ADA568152F Q38095507-48FACEA8-9E04-4C40-9E65-F1E9026E2C95 Q38129080-021FEB61-FB1E-47E6-B3EF-1339E16B3546 Q38172648-8EADF86F-A191-446E-AEAD-2C906E39F24D Q38245881-F864D8D1-ADDD-486A-92EC-D4EC03808AA5 Q38266751-34C92591-C2DB-4BF2-A5CC-F476AD4B58B3 Q38365574-747995FB-FB14-4B28-A41A-E7C60387201B Q38390459-98D3F54E-0376-40A2-A2BC-C599B05D296A Q38731152-ECA4D87D-EA52-4352-969A-68708127C4B2 Q38869709-FE9465FB-ABB4-41C6-A03F-DEDCB04AAD70 Q40203174-7EC599FD-93A6-4895-9D55-5D0442F573DF Q40253057-B6A17F98-5753-4200-B8A3-282AB077E23C Q40264818-7C36132A-E081-4C2D-B677-2B0AF7EA558C Q41298097-F9DB8AB6-AC9C-41CB-B3B0-1B3577D7CEE5 Q41906355-DCD2BE80-825D-4293-A5CB-FD8C8A956DF4 Q42174739-07D8DCE6-FCB4-492C-A39E-F148549B872E Q42227411-76BAE638-2204-4101-B587-BBDBAF6CB61D

P2860

Major source of antigenic peptides for the MHC class I pathway is produced during the pioneer round of mRNA translation.

http://www.wikidata.org/entity/Q35105327

description

2011 nî lūn-bûn

@nan

2011 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Major source of antigenic pept ...... eer round of mRNA translation.

@ast

Major source of antigenic pept ...... eer round of mRNA translation.

@en

type

label

Major source of antigenic pept ...... eer round of mRNA translation.

@ast

Major source of antigenic pept ...... eer round of mRNA translation.

@en

prefLabel

Major source of antigenic pept ...... eer round of mRNA translation.

@ast

Major source of antigenic pept ...... eer round of mRNA translation.

@en

P1433

Q35105327-343DFBE4-9B47-4902-8FFA-EA612C65303D

P1476

Q35105327-DBD278A0-47E8-466C-9FA1-0C8C7545E85D

P2093

Q35105327-1A1504BE-7EC5-4597-87F0-4A7825872C90

Q35105327-6A556123-DB25-4797-BB62-0547AFA3F9D8

Q35105327-71A9EC8A-6555-4AC6-911D-0FD902CED538

Q35105327-C15055E5-204A-4808-B928-B7495825879D

Q35105327-D87D131D-C9C5-4730-BAA8-67BC43A29480

P2860

Q35105327-0399C170-085D-47B9-AD32-83EADC120CBA

Q35105327-0639227E-8A3A-4A00-9B2F-A6C366E1D474

Q35105327-0642448B-CF7D-4C12-8BCB-8073647570CA

Q35105327-1B75C158-30AA-44CD-BE5E-F6921C8439F6

Q35105327-1DA73C5D-6868-4850-B448-6095B19F624C

Q35105327-2028F358-5855-4949-B4A5-B2ABD57AE29A

Q35105327-22E44B91-3C8E-4552-B746-7B5D028CB43E

Q35105327-25CA6250-1759-4BEB-A1EB-82D39D8E7B37

Q35105327-266E8110-BCA9-4D85-9712-5BAEA3CC8A46

Q35105327-2B49BF15-25CA-4599-B93B-7D3968FD5445

P304

Q35105327-D007AE78-3BA0-4DB7-A48E-D332C6B9F7F2

P31

Q35105327-8C6A3A0D-3716-46F3-80A5-D89D4F924B36

P356

Q35105327-D690EF54-47A0-453F-BBDF-5AB5B3FF5859

P407

Q35105327-E3CEB460-C6F3-4437-B796-525E4FCAAD3B

P433

Q35105327-ED01B0A9-644A-467D-8D46-513B03207956

P478

Q35105327-3AA9EA98-26D3-451D-BC34-5E706D2CEE5D

P50

Q35105327-CF9CBB7E-6E2F-4C95-A3DD-A6AFA229E6AE

Q35105327-FD66FD9B-6B7D-4328-A5F0-FB621AAF0D09

P577

Q35105327-B9E44313-B76D-48F9-A4AA-01FCF6895F03

P5875

Q35105327-76801FF7-4023-4388-9990-1A300749635C

P698

Q35105327-A4A19CCB-CEFA-447A-BA12-AD8A8B5278BD

P932

Q35105327-81D744D2-C147-4BAF-8E28-B403499B03C2

P356

PNAS.1104104108

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Major source of antigenic pept ...... eer round of mRNA translation.

@en

P2093

Chrysoula Daskalogianni

http://www.w3.org/2001/XMLSchema#string

Gabriela Imhoos

http://www.w3.org/2001/XMLSchema#string

Lea Heslop

http://www.w3.org/2001/XMLSchema#string

Robin Fåhraeus

http://www.w3.org/2001/XMLSchema#string

Sebastien Apcher

http://www.w3.org/2001/XMLSchema#string

P2860

Unanticipated antigens: translation initiation at CUG with leucine

eIF4G is required for the pioneer round of translation in mammalian cells

Upf1 phosphorylation triggers translational repression during nonsense-mediated mRNA decay

Repression of cap-dependent translation by 4E-binding protein 1: competition with p220 for binding to eukaryotic initiation factor-4E

eIF4 initiation factors: effectors of mRNA recruitment to ribosomes and regulators of translation

ERAAP customizes peptides for MHC class I molecules in the endoplasmic reticulum

Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules

Translation initiation at non-AUG triplets in mammalian cells

The nonsense-mediated decay RNA surveillance pathway

TAP1 mutant mice are deficient in antigen presentation, surface class I molecules, and CD4-8+ T cells

P304

11572-11577

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.1104104108

http://www.w3.org/2001/XMLSchema#string

P407

P433

28

http://www.w3.org/2001/XMLSchema#string

P478

108

http://www.w3.org/2001/XMLSchema#string

P50

Fabrice Lejeune

Bénédicte Manoury

P577

2011-06-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51253691

http://www.w3.org/2001/XMLSchema#string

P698

21709220

http://www.w3.org/2001/XMLSchema#string

P932

3136330

http://www.w3.org/2001/XMLSchema#string